Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting
Retrieved on:
Friday, April 8, 2022
Company, Abstract, FC, TF-1, NASDAQ, Forward-looking statement, TME, Interferon type II, GBM, Neoplasm, AACR, Half-life, Metastasis, Myelocyte, American Association, CEO, CD25, CD122, Brain, American Association for Cancer Research, Association, Tams, Annual general meeting, MDSC, MDNA, GLOBE, Type, IL13, EMA, Macrophage, News, Bifunctional, NK, FDA, Pharmaceutical industry, Vaccine
TORONTO and HOUSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting. Fc-MDNA413 is derived from Medicenna’s Superkine platform and comprises of an IL-13 super-antagonist (MDNA413) fused to the Fc domain for half-life extension.
Key Points:
- Fc-MDNA413 is derived from Medicennas Superkine platform and comprises of an IL-13 super-antagonist (MDNA413) fused to the Fc domain for half-life extension.
- Included in the AACR poster are data from in vitro and murine studies evaluating the affinity profile, target selectivity and anti-cancer activity of Fc-MDNA413 in a poorly immunogenic (cold) tumor model.
- These data demonstrate for the first time that an IL-13 Superkine, such as MDNA413, can block the pathways utilized by TAMs and MDSCs to promote cancer growth.
- A copy will also be posted to the Events andPresentations page of Medicennas website following the conclusion of the meeting.